Curaleaf launches hostile bid for Aurora Cannabis
Curaleaf Holdings launched a hostile bid for Aurora Cannabis, offering 0.3463 Curaleaf shares plus $0.75 cash per Aurora share, valuing the offer at $4 per share. Curaleaf cites a 45% premium to Aurora’s 30-day VWAP and says the deal could create a cannabis operator with $1.5B revenue and $350M adjusted EBITDA, plus $40M synergies. Aurora shares rose ~21% to ~$3.50.
How this was made
The 30-second read
Why it matters
The disclosed offer terms, premium, and immediate trading reaction create a time-sensitive M&A catalyst for both the acquirer and the target, with outcomes hinging on Aurora’s response and whether a formal bid or higher competing offer follows.
Market read
A hostile takeover offer with a stated premium and defined consideration structure is a direct repricing catalyst for ACB and a deal-probability catalyst for CURLF.
What to watch
The article notes no assurance a formal bid will be commenced and Aurora has not responded, so deal probability and timing remain the key swing variables.
Background
Curaleaf says it repeatedly attempted to engage Aurora’s leadership before going public with a hostile proposal.
Ticker impact
Curaleaf launched a hostile bid for Aurora, offering Curaleaf shares plus cash and valuing the deal at $4 per Aurora share.
Likely supportive for CURLF while the market prices in deal probability and potential bidding escalation.
The article reports a specific hostile offer structure, a stated premium, and immediate share reaction, which typically increases probability-weighted M&A expectations.
Aurora is the target of Curaleaf’s hostile acquisition offer, proposing 0.3463 CURLF shares plus $0.75 cash per ACB share.
Near-term bias upward versus pre-announcement levels, with volatility tied to whether Aurora responds or a higher bid emerges.
The article provides the offer terms, premium vs VWAP, and same-day stock jump, which directly affects ACB’s takeover valuation and negotiation leverage.
Market effects
Signals consolidation pressure in global cannabis, potentially resetting deal expectations and valuation multiples across licensed operators.
Could increase cross-border M&A attention for Europe and North America cannabis platforms.
May influence investor sentiment toward international cannabis roll-ups and EU-GMP capacity as strategic assets.
Counterpoint
Hostile bids often fail; if Aurora resists or pursues alternatives, the premium may unwind and acquirer shares can lag on financing or integration concerns.
Key entities
- acquirerCuraleaf Holdings Inc.
Launched a hostile bid to acquire Aurora, offering Curaleaf shares plus cash and citing strategic rationale and cost synergies.
- targetAurora Cannabis Inc.
Target of the hostile offer; shareholders would receive Curaleaf shares plus cash per Aurora share if the deal proceeds.
- executiveBoris Jordan
Curaleaf Chairman and CEO who sent letters to Aurora and commented on Aurora’s refusal to engage.
